Multifactorial risk factors for mortality after chemotherapy and radiotherapy for non-small cell lung cancer

Locally advanced non-small cell lung cancer (LA-NSCLC) when radically treated with standard concurrent chemoradiotherapy has a high local recurrence rate of approximately 30% at 2  years [1,2]. Additionally, the overall survival rates are low, around 30% in selected patients at 5 years in recent clinical trials investigating modern chemoradiotherapy [3–5]. Treatment-induced toxicity may partly be responsible for these unfavorable results, as indicated by the higher mort ality in the high-dose arm of RTOG0617 [2,3].

Source: Radiotherapy and Oncology - September 19, 2019 Category: Radiology Authors: Gilles Defraene, Frank J.W.M. Dankers, Gareth Price, Ewoud Schuit, Wouter van Elmpt, Soumia Arredouani, Maarten Lambrecht, Joost Nuyttens, Corinne Faivre-Finn, Dirk De Ruysscher Tags: Original Article Source Type: research